AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9725047 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX, 5-FU, and THP (Group A)
Number of subjects: 71
Study 9725047 — intervention group
Group type: COMPARATOR
Intervention: 5-FU alone (Group B)
Number of subjects: 71
Study 8199143 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad retractor
Number of subjects: 300
Study 8199143 — intervention group
Group type: COMPARATOR
Intervention: Howarth's periosteal elevator
Number of subjects: 300
Study 3379987 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality assurance intervention including predeveloped quality assurance packages and consultant services.
Number of subjects: 1525
Study 3379987 — intervention group
Group type: COMPARATOR
Intervention: Control group (no quality assurance intervention).
Number of subjects: 1525
Study 31504424 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (pPCI)
Number of subjects: 1572
Study 31504424 — intervention group
Group type: COMPARATOR
Intervention: Fibrinolysis
Number of subjects: 1572
Study 30957447 — intervention group
Group type: EXPERIMENTAL
Intervention: Surround needling
Number of subjects: 99
Study 30957447 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint injection
Number of subjects: 99
Study 30957447 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (surround needling + acupoint injection)
Number of subjects: 99
Study 28416501 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU, twice daily for 2 weeks)
Number of subjects: 50
Study 28416501 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice daily for 2 weeks)
Number of subjects: 50
Study 28416501 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 50
Study 28416501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 26091202 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 1000 IU/d
Number of subjects: 157
Study 26091202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 22972566 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketofol (1:1 mixture of 5 mg/ml ketamine and 5 mg/ml propofol)
Number of subjects: 80
Study 22972566 — intervention group
Group type: COMPARATOR
Intervention: Propofol 0.15 ml/kg
Number of subjects: 80
Study 22972566 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketofol
Number of subjects: 80
Study 22972566 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 80
Study 21938266 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents
Number of subjects: 46
Study 21938266 — intervention group
Group type: COMPARATOR
Intervention: Adults
Number of subjects: 46
Study 21938266 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study 18959799 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory Ergonomics (PE)
Number of subjects: 5759
Study 18959799 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (Control)
Number of subjects: 5759
Study 17038756 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention for mothers with problem drinking
Number of subjects: 25
Study 12949687 — intervention group
Group type: EXPERIMENTAL
Intervention: Epigam (1 tablet, 6 times a day)
Number of subjects: 20
Study 12949687 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (150 mg, 2 times a day)
Number of subjects: 20
Study 10836487 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 10836487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9055055 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release gemfibrozil, 1200 mg once daily
Number of subjects: 395
Study 9055055 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 395
Study 8338511 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-air-loss bed
Number of subjects: 84
Study 8338511 — intervention group
Group type: COMPARATOR
Intervention: 10-cm corrugated foam mattress
Number of subjects: 84
Study 8338511 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-air-loss bed (deep ulcers)
Number of subjects: 84
Study 8338511 — intervention group
Group type: COMPARATOR
Intervention: 10-cm corrugated foam mattress (deep ulcers)
Number of subjects: 84
Study 8338511 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-air-loss bed (superficial ulcers)
Number of subjects: 84
Study 8338511 — intervention group
Group type: COMPARATOR
Intervention: 10-cm corrugated foam mattress (superficial ulcers)
Number of subjects: 84
Study 8338511 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-air-loss bed (combined cure probability)
Number of subjects: 84
Study 31094588 — intervention group
Group type: EXPERIMENTAL
Intervention: Desogestrel 75 µg
Number of subjects: 150
Study 31094588 — intervention group
Group type: COMPARATOR
Intervention: Usual contraceptive
Number of subjects: 150
Study 29869351 — intervention group
Group type: EXPERIMENTAL
Intervention: Football
Number of subjects: 9
Study 29869351 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit-training
Number of subjects: 9
Study 29869351 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking
Number of subjects: 9
Study 26290587 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-initiated DMARD self-monitoring service
Number of subjects: 100
Study 26290587 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study 25236993 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin orally disintegrating tablet
Number of subjects: 56
Study 25236993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 22385692 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow heating regimen
Number of subjects: 54
Study 22385692 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow cooling regimen
Number of subjects: 54
Study 22385692 — intervention group
Group type: COMPARATOR
Intervention: Heating regimen
Number of subjects: 54
Study 20130241 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone plus rituximab
Number of subjects: 103
Study 20130241 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone alone
Number of subjects: 103
Study 18641372 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 12
Study 18641372 — intervention group
Group type: COMPARATOR
Intervention: Rosiglitazone
Number of subjects: 12
Study 16988138 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified milk (FM) with 5.8 mg iron as ferrous gluconate, 5.28 mg zinc as zinc oxide, and 48 mg ascorbic acid per 400 mL
Number of subjects: 0
Study 16988138 — intervention group
Group type: COMPARATOR
Intervention: Nonfortified milk (NFM) with 0.2 mg iron, 1.9 mg zinc, and 6.8 mg ascorbic acid per 400 mL
Number of subjects: 0
Study 16988138 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified milk (FM)
Number of subjects: 0
Study 12729425 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-mg warfarin initiation nomogram
Number of subjects: 201
Study 12729425 — intervention group
Group type: COMPARATOR
Intervention: 5-mg warfarin initiation nomogram
Number of subjects: 201
Study 10979111 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib, 400 mg twice per day (n = 3987)
Number of subjects: 8059
Study 10979111 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs (ibuprofen, 800 mg 3 times per day; n = 1985) or diclofenac, 75 mg twice per day (n = 1996)
Number of subjects: 8059
Study 9038440 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracocervical epidural block (lignocaine 1%)
Number of subjects: 36
Study 9038440 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar epidural block (lignocaine 1.5%)
Number of subjects: 36
Study 1573368 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires with questions about housing tenure
Number of subjects: 10000
Study 1573368 — intervention group
Group type: COMPARATOR
Intervention: Questionnaires without questions about housing tenure
Number of subjects: 10000
Study 1573368 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires with questions about ethnic origin
Number of subjects: 10000
Study 1573368 — intervention group
Group type: COMPARATOR
Intervention: Questionnaires without questions about ethnic origin
Number of subjects: 10000
Study 4070708 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.75%
Number of subjects: 24
Study 4070708 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.5%
Number of subjects: 24
Study 31498784 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) package for neonatal resuscitation
Number of subjects: 89014
Study 29943384 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal vaginal suppository containing 10% myrtle aqueous extract and 0.5% myrtle essential oil, prescribed for 3 months (20 suppositories at each menstrual cycle)
Number of subjects: 60
Study 29943384 — intervention group
Group type: COMPARATOR
Intervention: Placebo vaginal suppository, prescribed for 3 months (20 suppositories at each menstrual cycle)
Number of subjects: 60
Study 29943384 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal vaginal suppository containing 10% myrtle aqueous extract and 0.5% myrtle essential oil
Number of subjects: 60
Study 29943384 — intervention group
Group type: COMPARATOR
Intervention: Placebo vaginal suppository
Number of subjects: 60
Study 26873229 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab HYP (150 mg SC every 4 weeks)
Number of subjects: 1657
Study 26873229 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab HYP (100-300 mg SC)
Number of subjects: 1657
Study 26873229 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab HYP
Number of subjects: 1657
Study 24509626 — intervention group
Group type: COMPARATOR
Intervention: Simulated altitude at sea level
Number of subjects: 10
Study 24509626 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated altitude at 2000 m
Number of subjects: 10
Study 24509626 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated altitude at 3000 m
Number of subjects: 10
Study 24509626 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated altitude at 4000 m
Number of subjects: 10
Study 23600304 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cell autovaccine loaded with autologous tumor cell lysate
Number of subjects: 0
Study 23600304 — intervention group
Group type: COMPARATOR
Intervention: Standard DC-autovaccine
Number of subjects: 0
Study 21171135 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE) therapy
Number of subjects: 24
Study 21171135 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 24
Study 17583594 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐line auditory‐evoked potential monitor (Group AAI, n = 100)
Number of subjects: 200
Study 17583594 — intervention group
Group type: COMPARATOR
Intervention: Aspect A‐2000 bispectral index monitor (Group BIS, n = 100)
Number of subjects: 200
Study 17583594 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐line auditory‐evoked potential monitor (Group AAI)
Number of subjects: 200
Study 17583594 — intervention group
Group type: COMPARATOR
Intervention: Aspect A‐2000 bispectral index monitor (Group BIS)
Number of subjects: 200
Study 16381256 — intervention group
Group type: EXPERIMENTAL
Intervention: pancuronium
Number of subjects: 60
Study 16381256 — intervention group
Group type: EXPERIMENTAL
Intervention: cisatracurium
Number of subjects: 60
Study 16381256 — intervention group
Group type: COMPARATOR
Intervention: vecuronium
Number of subjects: 60
Study 12195876 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine and famciclovir combination therapy
Number of subjects: 20
Study 12195876 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine and famciclovir combination therapy with IFN-alpha 2b
Number of subjects: 20
Study 10096821 — intervention group
Group type: EXPERIMENTAL
Intervention: House dust mite avoidance therapy (including allergen-impermeable encasement of mattresses and other strategies)
Number of subjects: 0
Study 10096821 — intervention group
Group type: COMPARATOR
Intervention: House dust mite exposure
Number of subjects: 0
Study 7534055 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated cardiopulmonary bypass
Number of subjects: 36
Study 7534055 — intervention group
Group type: COMPARATOR
Intervention: Control (non-heparin-coated) cardiopulmonary bypass
Number of subjects: 36
Study 2240543 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal tube orientation of -90 degrees (bevel facing posteriorly)
Number of subjects: 100
Study 2240543 — intervention group
Group type: COMPARATOR
Intervention: Tracheal tube orientation of 0 degrees (bevel facing left)
Number of subjects: 100
Study 2240543 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a laryngoscope during intubation
Number of subjects: 100
Study 2240543 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngoscope left in mouth while rail-roading a tube over the bougie
Number of subjects: 100
Study 678387 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg long‐acting capsule formulation (LA)
Number of subjects: 12
Study 678387 — intervention group
Group type: COMPARATOR
Intervention: 80 mg twice a day regimen (CP80)
Number of subjects: 12
Study 30943777 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated corneal cross-linking (18 mW/cm2, 5 min)
Number of subjects: 62
Study 30943777 — intervention group
Group type: COMPARATOR
Intervention: Standard corneal cross-linking (3 mW/cm2, 30 min)
Number of subjects: 62
Study 30943777 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated corneal cross-linking
Number of subjects: 62
Study 30943777 — intervention group
Group type: COMPARATOR
Intervention: Standard corneal cross-linking
Number of subjects: 62
Study 30309970 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential DMARD-monotherapy (sulfasalazine or methotrexate)
Number of subjects: 94
Study 30309970 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy MTX + 6 weeks prednisolone
Number of subjects: 94
Study 30309970 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy MTX + etanercept
Number of subjects: 94
Study 28925749 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac telerehabilitation programme for 6 months
Number of subjects: 126
Study 28925749 — intervention group
Group type: COMPARATOR
Intervention: No tele-intervention
Number of subjects: 126
Study 25710801 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate (SC) 1600 mg, three times a day
Number of subjects: 117
Study 23484743 — intervention group
Group type: EXPERIMENTAL
Intervention: FSRS curriculum (Experimental Group)
Number of subjects: 53
Study 23484743 — intervention group
Group type: COMPARATOR
Intervention: Crossover group (Control Group)
Number of subjects: 53
Study 21849147 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailuo Shutong Granule
Number of subjects: 108
Study 21849147 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirudoid cream
Number of subjects: 108
Study 21849147 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (Mailuo Shutong Granule + Hirudoid cream)
Number of subjects: 108
Study 19433997 — intervention group
Group type: EXPERIMENTAL
Intervention: Team care with proactive clinical pharmacist services (medication history, patient-care round participation, resolution of drug-related issues, discharge counseling)
Number of subjects: 452
Study 19433997 — intervention group
Group type: EXPERIMENTAL
Intervention: Team care with proactive clinical pharmacist services
Number of subjects: 452
Study 19433997 — intervention group
Group type: COMPARATOR
Intervention: Usual care with traditional reactive clinical pharmacist services
Number of subjects: 452
Study 16807001 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoropolymer-coated Dacron grafts
Number of subjects: 198
Study 16807001 — intervention group
Group type: COMPARATOR
Intervention: PTFE grafts
Number of subjects: 198
Study 14616458 — intervention group
Group type: EXPERIMENTAL
Intervention: tolterodine ER 4 mg once daily
Number of subjects: 608
Study 14616458 — intervention group
Group type: EXPERIMENTAL
Intervention: oxybutynin IR 3 mg three times daily
Number of subjects: 608
Study 14616458 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 608
Study 10964190 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematized education on HIV/AIDS
Number of subjects: 141
Study 8813791 — intervention group
Group type: EXPERIMENTAL
Intervention: Straight anastomosis
Number of subjects: 33
Study 8813791 — intervention group
Group type: COMPARATOR
Intervention: Colonic J pouch anastomosis
Number of subjects: 33
Study 1359166 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing with priming (0.005 mg.kg‐1 vecuronium as priming doses followed by 0.15 mg.kg‐1 vecuronium)
Number of subjects: 40
Study 1359166 — intervention group
Group type: COMPARATOR
Intervention: Timing (0.15 mg.kg‐1 vecuronium)
Number of subjects: 40
Study 1359166 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 4014048 — intervention group
Group type: EXPERIMENTAL
Intervention: milrinone
Number of subjects: 14
Study 30184110 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ‐9375 (250 μg/mL)
Number of subjects: 15
Study 30184110 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ‐9375 (2.5, 25, and 250 μg/mL)
Number of subjects: 15
Study 30184110 — intervention group
Group type: COMPARATOR
Intervention: Bivalirudin (6 μg/mL)
Number of subjects: 15
Study 30184110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30898238 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganglion plexus (GP) ablation
Number of subjects: 240
Study 28122529 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary costs of Alzheimer's disease (AD)
Number of subjects: 2500
Study 26749229 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope video laryngoscope (GVL)
Number of subjects: 97
Study 26749229 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy
Number of subjects: 97
Study 23233713 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib-melphalan-prednisone (VMP)
Number of subjects: 682
Study 23233713 — intervention group
Group type: COMPARATOR
Intervention: Melphalan-prednisone (MP)
Number of subjects: 682
Study 21787883 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovulation induction (OI) with aromatase inhibitor
Number of subjects: 0
Study 21787883 — intervention group
Group type: COMPARATOR
Intervention: Ovulation induction (OI) with gonadotropins or clomiphene citrate
Number of subjects: 0
Study 19340902 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of oral allopurinol at 15 h and 3 h before ERCP
Number of subjects: 170
Study 19340902 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo at the same times as the allopurinol group
Number of subjects: 170
Study 16957651 — intervention group
Group type: COMPARATOR
Intervention: mini-subvastus approach
Number of subjects: 60
Study 16957651 — intervention group
Group type: COMPARATOR
Intervention: quadriceps-sparing approach
Number of subjects: 60
Study 15103755 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum concentrations of prolactin in breast cancer patients
Number of subjects: 46
Study 15103755 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperprolactinemic patients with metastatic breast cancer
Number of subjects: 46
Study 15103755 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum concentration of prolactin before treatment in hyperprolactinemic patients
Number of subjects: 46
Study 11704877 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing glasses from the age of six months
Number of subjects: 289
Study 11704877 — intervention group
Group type: COMPARATOR
Intervention: Not wearing glasses (control group)
Number of subjects: 289
Study 11704877 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing glasses
Number of subjects: 289
Study 9146905 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar alcohols (polyols) in aqueous solutions
Number of subjects: 0
Study 7712903 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 50 mg followed by 25 mg every 12 hours up to a total dose of 150 mg + misoprostol 600 micrograms (Group 1)
Number of subjects: 600
Study 7712903 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 50 mg followed by 25 mg every 12 hours up to a total dose of 150 mg + PG05 1 mg vaginal suppository (Group 2)
Number of subjects: 600
Study 7712903 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg + misoprostol 600 micrograms (Group 3)
Number of subjects: 600
Study 7712903 — intervention group
Group type: COMPARATOR
Intervention: PG05 group (Group 2)
Number of subjects: 600
Study 3122551 — intervention group
Group type: EXPERIMENTAL
Intervention: MgCl2 infusate
Number of subjects: 35
Study 3122551 — intervention group
Group type: COMPARATOR
Intervention: MgSO4 infusate
Number of subjects: 35
Study 31096843 — intervention group
Group type: EXPERIMENTAL
Intervention: web-based expert support self-management program (WEST)
Number of subjects: 60
Study 31096843 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 29853429 — intervention group
Group type: EXPERIMENTAL
Intervention: Improving dietary quality (measured by the Alternate Health Eating Index - AHEI)
Number of subjects: 87
Study 29853429 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline consumption of carbohydrate, sugars, fibre, magnesium, and AHEI score
Number of subjects: 87
Study 27931551 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) 20mg tid, n=50
Number of subjects: 100
Study 24200748 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50mg daily for 4 weeks)
Number of subjects: 54
Study 24200748 — intervention group
Group type: COMPARATOR
Intervention: Trichlormethiazide (4mg daily for 4 weeks)
Number of subjects: 54
Study 24200748 — intervention group
Group type: COMPARATOR
Intervention: Normotensive control subjects
Number of subjects: 54
Study 23332861 — intervention group
Group type: COMPARATOR
Intervention: FF/VI 200/25 μg
Number of subjects: 1224
Study 23332861 — intervention group
Group type: COMPARATOR
Intervention: FF/VI 100/25 μg
Number of subjects: 1224
Study 23332861 — intervention group
Group type: COMPARATOR
Intervention: VI 25 μg
Number of subjects: 1224
Study 23332861 — intervention group
Group type: COMPARATOR
Intervention: FF 200 μg
Number of subjects: 1224
Study 21715530 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (125 mg)
Number of subjects: 16
Study 21715530 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine (120 mg)
Number of subjects: 16